KBC Group NV Sells 834 Shares of Zimmer Biomet Holdings, Inc. $ZBH

KBC Group NV cut its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.9% during the 2nd quarter, Holdings Channel reports. The firm owned 27,906 shares of the medical equipment provider’s stock after selling 834 shares during the quarter. KBC Group NV’s holdings in Zimmer Biomet were worth $2,545,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Accent Capital Management LLC bought a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $35,000. Cullen Frost Bankers Inc. increased its position in shares of Zimmer Biomet by 1,452.4% during the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 305 shares during the last quarter. Zions Bancorporation National Association UT bought a new stake in Zimmer Biomet during the first quarter worth $48,000. Hilltop National Bank bought a new stake in Zimmer Biomet during the second quarter worth $42,000. Finally, Brooklyn Investment Group boosted its position in Zimmer Biomet by 45.9% in the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 145 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

NYSE ZBH opened at $89.86 on Monday. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The company has a market cap of $17.81 billion, a PE ratio of 21.86, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a 52 week low of $85.33 and a 52 week high of $114.72. The firm’s 50-day simple moving average is $98.56 and its two-hundred day simple moving average is $97.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. The company had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were given a dividend of $0.24 per share. The ex-dividend date was Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio is currently 23.76%.

Insider Activity

In other news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.39% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on ZBH. Barclays decreased their target price on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research report on Wednesday, November 5th. JPMorgan Chase & Co. restated a “neutral” rating and set a $100.00 price objective (down previously from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Canaccord Genuity Group reduced their target price on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research report on Monday, November 10th. Finally, Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Sunday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $109.00.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.